Literature DB >> 9010345

Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate.

N Bruchovsky1, M D Sadar, K Akakura, S L Goldenberg, K Matsuoka, P S Rennie.   

Abstract

The expression of 5alpha-reductase type 1 and type 2 isoenzymes in hyperplastic human prostate tissue and several human prostate cell lines was investigated by Northern blot analyses, reverse transcription-polymerase chain reaction (RT-PCR), and enzyme activity. Separation of stroma and epithelium was confirmed histologically and only preparations with no apparent contamination were employed in the subsequent studies. Poly(A)+ RNA was isolated from stromal and epithelial fractions and analysed by Northern blot and RT-PCR. Inhibition of epithelial and stromal 5alpha-reductase activities by 17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan- 3-one (4MA) was assessed using a range of concentrations between 10(-13) and 10(-5) M. Results from Northern blot analyses and RT-PCR showed that the prostate stroma expressed 5alpha-reductase type 1 and type 2 isoenzymes, whereas the prostate epithelium only expressed 5alpha-reductase type 1. This was consistent with biphasic inhibition of 5alpha-reductase activity by 4MA in stroma and monophasic inhibition in epithelium. Cultured epithelial cells derived from human prostate only expressed 5alpha-reductase type 1 and had Vmax and Km values that approximated the lower end of the range reported for surgically removed prostate epithelium. The foregoing data explains the disparate activities of 5alpha-reductase, previously reported, in stroma and epithelium. The differential localization of these isoenzymes in the prostate suggests that future therapy of androgen-sensitive disease may be more successful through the use of selective inhibitors of the different 5alpha-reductase isoenzymes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9010345     DOI: 10.1016/s0960-0760(96)00125-2

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

Review 1.  [Chemoprevention of prostate cancer].

Authors:  B Djavan; I Thompson; M S Michel; M Waldert; C Seitz
Journal:  Urologe A       Date:  2004-05       Impact factor: 0.639

2.  Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.

Authors:  Sibylle Marihart; Mike Harik; Bob Djavan
Journal:  Rev Urol       Date:  2005

Review 3.  The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

Authors:  Donald J Tindall; Roger S Rittmaster
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

4.  Expression of 5alpha-reductases in human epithelial ovarian cancer: its correlation with androgen receptor status.

Authors:  J I Akahira; T Suzuki; K Ito; A D Darnel; T Moriya; S Sato; N Yaegashi; K Okamura; H Sasano
Journal:  Jpn J Cancer Res       Date:  2001-09

5.  5-alpha-reductase and the development of the human prostate.

Authors:  C Radmayr; A Lunacek; C Schwentner; J Oswald; H Klocker; G Bartsch
Journal:  Indian J Urol       Date:  2008-07

6.  Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells.

Authors:  John P Wiebe; Michael J Lewis
Journal:  BMC Cancer       Date:  2003-03-22       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.